Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 7 publications
(9 reference statements)
0
5
0
Order By: Relevance
“…trastuzumab, pertuzumab and afatinib, and others are being tested in ongoing clinical trials 58 . In CMC and FMC, HER2 overexpression is in the same range as in human breast cancers 82 - 85 . Nonetheless, studies of HER2-targeting in these veterinary patients have been so far limited to in vitro evaluations.…”
Section: Human Epidermal Growth Factor Receptormentioning
confidence: 86%
“…trastuzumab, pertuzumab and afatinib, and others are being tested in ongoing clinical trials 58 . In CMC and FMC, HER2 overexpression is in the same range as in human breast cancers 82 - 85 . Nonetheless, studies of HER2-targeting in these veterinary patients have been so far limited to in vitro evaluations.…”
Section: Human Epidermal Growth Factor Receptormentioning
confidence: 86%
“…These retrospective results indicate that mammary gland tumors found in elderly or intact bitches are more likely to be malignant. This could be related to clinical problems because the incidence of mammary gland tumors has increased owing to the longer life span based on humanized lifestyle and better medical treatment of domestic animals [ 36 , 38 ]. This problem can be more severe in countries like Europe where ovariohysterectomy is not frequently performed, because the incidence of mammary gland tumors is reported to be 50% to 70% of all neoplasias developed in intact bitches [ 6 , 7 , 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…However, its specific role is still a controversial issue, probably due to the tumor heterogeneity but also because of the different techniques, methodologies and protocols used in quantification of CXCR4 and CXCL12 expression. On the other hand, the information regarding CXCR4/CXCL12 axis during the development of FMC is almost absent, despite the fact FMC being considered as suitable cancer model [ 17 19 ]. Recently our group identified CXCL12 as a reliable blood serum marker for FMC, being predominantly relevant for HER2-overexpressing tumors diagnosis [ 24 ].…”
Section: Discussionmentioning
confidence: 99%